BJH - volume 10, issue 7, november 2019
J. Depaus
Editorial for the contribution of T. Goos et al., entitled: A single-center retrospective study of patients with systemic mastocytosis at University Hospital Leuven
BELG J HEMATOL 2019;10(7):265-76)
(BELG J HEMATOL 2019;10(7):264)
Read moreBJH - volume 9, issue 7, december 2018
J. Depaus , A. Bosly MD, PhD, H. Tilly , B. Coiffier , M. André MD
Rituximab with cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) is the standard treatment for diffuse large B-cell lymphoma and is able to cure 50–60% of the patients. However, patients resistant to or in early relapse after R-CHOP have a very poor prognosis with a median overall survival of only six months, and very few patients have a long survival. Double-hit lymphoma (rearrangement MYC and BCL2) has a major risk of refractoriness, and more intense chemotherapy than R-CHOP is recommended. Early PET-CT could identify resistance to conventional chemotherapy. Intensification with autologous or allogeneic stem cell transplantation is recommended in case of a response to salvage regimen. New agents are expected and chimeric antigen receptor T-cell therapy is a very promising approach.
(BELG J HEMATOL 2018;9(7):249–53)
Read moreBJH - volume 9, issue 7, december 2018
O. Stas , E. Mourin MD, J. Depaus , F-X. Hanin , I. Theate , M. André MD
We report the case of a 69-year-old woman who presented an aggressive breast implant-associated anaplastic large cell lymphoma with supra- and infradiaphragmatic disease. The diagnosis was made 17 years after her first prosthesis, following a right breast carcinoma, and three years after the replacement of this first prosthesis. Breast implant-associated anaplastic large cell lymphoma is a rare form of non-Hodgkin lymphoma caused by a breast implant. Unique features of this case include the fast clinical extension of a lymphoma that is indolent in the vast majority of the cases. Indeed, less than two months after the first symptoms on the breast, cutaneous metastasis appeared on the right arm. The key diagnosis exams are histology and immunohistochemistry including CD30 and cytotoxic markers and a PET-scan to evaluate the extension of the disease. The treatment should include removal of the prosthesis and any associated mass. Local residual or unresectable disease may benefit from radiation therapy to the chest wall. For regional lymph node involvement or confirmed extended disease, adjuvant chemotherapy more in line with systemic anaplastic large cell lymphoma anaplastic lymphoma kinase-negative treatments is recommended. Finally, brentuximab vedotin, an anti-CD30 monoclonal antibody, showed encouraging results in refractory disease but still needs more prospective trials.
(BELG J HEMATOL 2018;9(7):279–84)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
O. Stas , E. Mourin MD, J. Depaus , F-X. Hanin , I. Theate , M. André MD
BJH - volume 5, issue Abstract Book BHS, january 2014
J. Depaus , T. Clozel , P. Gaulard , C. Haioun
Top
